InspireMD (NSPR) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Lake Street Maintains InspireMD(NSPR.US) With Buy Rating, Maintains Target Price $5
Moomoo NewsDec 12 09:31 ET · Ratings
InspireMD Says Shore Will Remain as CFO Until His Successor Is Appointed >NSPR
Dow JonesDec 12 07:01 ET
Press Release: InspireMD Announces Expected Retirement of Its CFO Craig Shore and CFO Transition in 2025
Dow JonesDec 12 07:00 ET
InspireMD Initiated at Buy by Lake Street
Dow JonesDec 11 13:59 ET · Ratings
InspireMD Price Target Announced at $5.00/Share by Lake Street
Dow JonesDec 11 13:59 ET · Ratings
InspireMD Analyst Ratings
BenzingaDec 11 13:46 ET · Ratings

Comments

Trytosaveabit

Oct 15 06:14

Update

$InspireMD (NSPR.US)$ InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the Cguard Prime Carotid Stent System

Jaguar8

Oct 7 06:02

NEWS

$InspireMD (NSPR.US)$
InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System
InspireMD (Nasdaq: NSPR) has received FDA approval for its Investigational Device Exemption (IDE) Application to initiate the CGUARDIANS II pivotal studyof the CGuard Prime 80cm Carotid Stent System for transcarotid revascularization (TCAR) procedures. This approval marks a significant milestone in the company's ...

1

Jaguar8

Sep 16 06:01

NEWS

$InspireMD (NSPR.US)$
InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System
PMA based on overwhelmingly positive results from the pivotal C-GUARDIANS clinical study that were first presented at LINC 2024 in May
U.S. commercial launch anticipated in H1 2025, if approved
TEL AVIV, Israel and MIAMI, Sept. 16, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prev...

maddhatter

Jul 17 20:20

$InspireMD (NSPR.US)$ the mesh stint will become FDA approved. When is the question.

Trytosaveabit

Jul 1 06:08

$InspireMD (NSPR.US)$ InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million

NSPR InspireMD

Trade Overview

Capital Trend

News

Comments